Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Penn study may lead the way for first medication to treat cocaine addiction

11.01.2005


Breakout data suggests a wake-promoting agent promotes cocaine abstinence

Cocaine dependence is a major public health problem affecting thousands of people around the globe. Despite years of active research there are still no approved medications for the treatment of this life-shattering addiction. Researchers are now hopeful that may soon change based on the results of a controlled study done at the University of Pennsylvania School of Medicine. The study’s findings can be found in the January issue of Journal of Neuropsychopharmacology and on-line at www.neuropsychopharmacology.org. Penn investigators have identified Modafinil – a wake-promoting agent approved for the treatment of narcolepsy – as a possible medicinal treatment for cocaine dependence. In a double-blind, placebo-controlled trial, researchers found Modafinil promoted cocaine abstinence in treatment-seeking outpatients. Modafinil was also shown to blunt cocaine-induced euphoria in a prior study conducted by the same research group, perhaps explaining its clinical advantage. "If confirmed by further investigation, this could be the breakthrough we have been waiting for," says Charles Dackis, MD, Chief of Psychiatry at the University of Pennsylvania Medical Center – Presbyterian, and the study’s principal investigator.

"Cocaine is capable of destroying not only the lives of those addicted, but also those around them," adds Dackis. "An effective treatment for cocaine addiction would help those most vulnerable in our society to overpower their addiction and regain control in their lives." The trial was conducted at Penn’s Treatment Research Center between 2002 and 2003. It involved a sample of 62 cocaine-dependent patients (aged 25-63) free of significant medical and psychiatric conditions. All participants were from the Philadelphia area. After initial screenings, eligible patients were randomized to a single morning dose of Modafinil (400 mg), or matching placebo tablets, that was continued for eight weeks along with twice-weekly cognitive behavioral therapy (CBT). Thirty participants were treated with Modafinil; and 32 were given placebo.



The primary efficacy measure was cocaine abstinence, measured by urine toxicity testing. Secondary measures were craving, cocaine withdrawal, retention, and adverse events. Modafinil-treated patients provided significantly more cocaine-negative urine samples over the eight-week period than those given placebo, and were more likely to achieve protracted cocaine abstinence.

Along with this finding, Penn researchers also discovered that there were no serious adverse events in those treated with Modafinil, and none of the patients failed to complete the study as a result of any side effects. "These preliminary results are very promising and three larger studies of modafinil for cocaine dependence are currently underway, including one at Penn," adds Dr. Dackis.

This study was funded by research grants from the National Institute of Drug Abuse. Cephalon Inc. provided Modafinil and matched placebo tablets, but had no participation in the design or implementation of the trial. Other Penn researchers contributing to the study are Kyle M. Kampman, MD, Kevin G. Lynch, PhD, Helen M. Pettinati, PhD, and Charles O’Brien, MD, PhD.

Ed Federico | EurekAlert!
Further information:
http://www.neuropsychopharmacology.org
http://www.uphs.upenn.edu/news

More articles from Studies and Analyses:

nachricht Drone vs. truck deliveries: Which create less carbon pollution?
31.05.2017 | University of Washington

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Supersensitive through quantum entanglement

28.06.2017 | Physics and Astronomy

X-ray photoelectron spectroscopy under real ambient pressure conditions

28.06.2017 | Physics and Astronomy

Mice provide insight into genetics of autism spectrum disorders

28.06.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>